Enzyme replacement therapy in Fabry disease: a randomized controlled trial. - Wikidata - awgldk - TriplyDB

Enzyme replacement therapy in Fabry disease: a randomized controlled trial.

Enzyme replacement therapy in Fabry disease: a randomized controlled trial.

http://www.wikidata.org/entity/Q33949356

about

Treatment of Fabry disease: outcome of a comparative trial with agalsidase alfa or beta at a dose of 0.2 mg/kg A plant-derived recombinant human glucocerebrosidase enzyme--a preclinical and phase I investigation Fabry disease: recent advances in pathology, diagnosis, treatment and monitoring Early diagnosis of peripheral nervous system involvement in Fabry disease and treatment of neuropathic pain: the report of an expert panel Enzyme replacement therapy for Anderson-Fabry disease Enzyme replacement therapy for Anderson-Fabry disease Safety and efficacy of enzyme replacement therapy in the nephropathy of Fabry disease Patients affected with Fabry disease have an increased incidence of progressive hearing loss and sudden deafness: an investigation of twenty-two hemizygous male patients.Enzyme replacement reverses abnormal cerebrovascular responses in Fabry disease Enzyme replacement therapy for Anderson-Fabry disease Pain management strategies for neuropathic pain in Fabry disease--a systematic review 5p deletions: Current knowledge and future directions.Neurological diseases and pain Drug treatment of inborn errors of metabolism: a systematic review Catalytic mechanism of human alpha-galactosidase Interconversion of the Specificities of Human Lysosomal Enzymes Associated with Fabry and Schindler Diseases The Molecular Basis of Pharmacological Chaperoning in Human α-Galactosidase Fabry disease defined: baseline clinical manifestations of 366 patients in the Fabry Outcome Survey A phase II/III clinical study of enzyme replacement therapy with idursulfase in mucopolysaccharidosis II (Hunter syndrome)Life expectancy and cause of death in males and females with Fabry disease: findings from the Fabry Registry Agalsidase alfa: a review of its use in the management of Fabry disease Comparative analysis of acid sphingomyelinase distribution in the CNS of rats and mice following intracerebroventricular delivery Receptor-mediated endocytosis of α-galactosidase A in human podocytes in Fabry disease A distinct urinary biomarker pattern characteristic of female Fabry patients that mirrors response to enzyme replacement therapy Oral Migalastat HCl Leads to Greater Systemic Exposure and Tissue Levels of Active α-Galactosidase A in Fabry Patients when Co-Administered with Infused Agalsidase Lysosomal Re-acidification Prevents Lysosphingolipid-Induced Lysosomal Impairment and Cellular Toxicity Temporal intradiploic dilative vasculopathy: an additional pathogenic factor for the hearing loss in fabry disease?Fabry disease in latin america: data from the fabry registry.Skin-impedance in Fabry Disease: a prospective, controlled, non-randomized clinical study Recombinant enzyme therapy for Fabry disease: absence of editing of human alpha-galactosidase A mRNA.Effects of enzyme replacement therapy on pain and health related quality of life in patients with Fabry disease: data from FOS (Fabry Outcome Survey).Time to treatment benefit for adult patients with Fabry disease receiving agalsidase β: data from the Fabry Registry.Fabry disease and the skin: data from FOS, the Fabry outcome survey.Arrhythmias in Fabry cardiomyopathy.Angiokeratomas of Fabry successfully treated with intense pulsed light.Genetics of atherothrombotic and lacunar stroke Immunomodulatory gene therapy prevents antibody formation and lethal hypersensitivity reactions in murine pompe disease.Fabry nephropathy: a review - how can we optimize the management of Fabry nephropathy?Effectiveness of enzyme replacement therapy in Fabry disease: Long term experience in Argentina.Prognostic indicators of renal disease progression in adults with Fabry disease: natural history data from the Fabry Registry

P2860

Q21004071-6E38AAF7-E774-45CA-84F1-0F6CA5FF988E Q21092136-62CC615F-F2C1-489E-8D53-29DB315010A7 Q21202889-29728620-88E5-497D-A580-04F5959C3626 Q21261394-219BFE11-24D9-48A8-8A38-AF1CD8C890A7 Q24200877-F68542B8-6D72-4E6A-95F6-3AFFB7397031 Q24235483-F6F9BEB0-4066-4EE1-A9A3-5DE21F15035E Q24650910-8EE6937E-648C-40B3-B293-211081C10BA4 Q24794000-A9C92DE2-CEB4-4564-A9A4-989A5D62944E Q24795877-6EBC6517-5FAE-4441-BB59-5D2E1344E219 Q26471010-AF706E10-C07D-434A-A627-B0BBFF698479 Q26766561-7FFEF6AD-C3FF-4B07-B769-EC3EE8F8C777 Q26800129-33ABD2EA-EE7A-4452-B28B-5D33C82102D0 Q26822891-D2CD7774-3E8E-4491-812D-4DC6ABE0B306 Q26864796-D487FBFC-087C-4A83-9377-5C8C3A311F6A Q27658332-DD5B0F35-F890-46EF-BFD2-C3993C55F42F Q27661323-F565B1AC-AEA6-4B72-A538-91072B3CAF83 Q27676392-54DC822C-CBC7-4F4B-93C9-8612E4F3E6A5 Q28250905-642AF7E4-A12C-4DFB-A9D9-6F29A8960BD8 Q28258072-F816D8B7-9041-4258-AC99-649230A7A137 Q28258153-F4881F9A-862B-448B-8762-52F8F00F1ADE Q28274194-33E2109D-DAF7-44AF-B241-6624C06D9255 Q28476819-20A30911-5E13-4AA0-8F21-369477E7B2A1 Q28477142-CDDE1E40-786B-4F7B-9998-47858D117CD7 Q28478586-18C022C0-516D-4D83-A694-708878E34066 Q28547115-28910B7F-D536-4739-A656-34BB4BC67014 Q28555118-2C80F553-E608-4CC0-B824-5802A2F50E9B Q30458149-E079CA00-BDEC-431C-B4B4-162F87E38771 Q30592389-4E9DEF2F-E9B1-485D-99FE-9A6AEC11B21A Q30850675-D8F5A56E-4BE5-4FE0-A41D-2321B8B5EF69 Q30873303-7450EC3E-E9B7-40B9-BD19-C139D85BCE31 Q30983988-3FD625CA-2779-44A2-B61C-77F1B5F3947A Q31060724-CB265E8E-2410-439A-A286-98B982BFA8CD Q31116015-7884F4FE-182B-47D8-AF3A-55596D4D1AE4 Q33161649-BD409BFA-4C1B-493E-AF08-31C557CAB700 Q33373387-745FED3C-026D-4915-A019-6CC9DACA5791 Q33557583-32AC3B82-9EA0-494F-9A77-BF3DBCE88A1F Q33637062-EA3E1E6D-EC00-4198-AAF3-E9EABBEF0628 Q33645550-178DE5A5-10E9-4487-A4A4-3C5D137150F5 Q33652370-3D506ACE-ABE3-48F4-B1D8-209F696597FA Q33683158-3BDEAFD4-9F96-4BA7-9374-8BA4FA172E65

P2860

Enzyme replacement therapy in Fabry disease: a randomized controlled trial.

http://www.wikidata.org/entity/Q33949356

description

2001 nî lūn-bûn

@nan

2001 թուականի Յունիսին հրատարակուած գիտական յօդուած

@hyw

2001 թվականի հունիսին հրատարակված գիտական հոդված

@hy

2001年の論文

@ja

2001年論文

@yue

2001年論文

@zh-hant

2001年論文

@zh-hk

2001年論文

@zh-mo

2001年論文

@zh-tw

2001年论文

@wuu

name

Enzyme replacement therapy in Fabry disease: a randomized controlled trial.

@ast

Enzyme replacement therapy in Fabry disease: a randomized controlled trial.

@en

type

label

Enzyme replacement therapy in Fabry disease: a randomized controlled trial.

@ast

Enzyme replacement therapy in Fabry disease: a randomized controlled trial.

@en

prefLabel

Enzyme replacement therapy in Fabry disease: a randomized controlled trial.

@ast

Enzyme replacement therapy in Fabry disease: a randomized controlled trial.

@en

P1433

Q33949356-483C973F-9E01-4FFD-981A-9549BBB34451

P1476

Q33949356-C39F1A86-D3BE-4EE1-B5F8-16846F7DABBA

P2093

Q33949356-5592FC02-5E09-43A8-BF72-A13293218ED8

Q33949356-5A754C09-FF1D-4DB0-BA38-8476A8B48E5D

Q33949356-6972F13F-3711-4E6B-963D-18DA9EC70583

Q33949356-89ADBB9E-D344-4E72-92E5-17EF80619DC8

Q33949356-93627E34-DBD8-42C8-B439-D10A662C3630

Q33949356-B388C863-A726-4964-AD10-E9777F4EBDE6

Q33949356-C16CA447-3ADB-4C4F-90CB-3B258A49DFB9

Q33949356-D83BDDB0-F809-42D4-9FFB-391F5938D058

P304

Q33949356-B156A600-4301-4F65-9B76-CDBBDE6AEB13

P31

Q33949356-BB68FF27-841A-47F7-A09C-9819A553F179

P356

Q33949356-19A7CA16-A5EA-4843-8C08-716E1F7CA204

P407

Q33949356-E0D251AC-5490-4B7E-AB1A-EB2E575ECB9A

P433

Q33949356-ED38553F-3A8B-47BC-BDC5-C86D4C20B777

P478

Q33949356-076343D4-2324-4F8D-9421-08FDD08D07AB

P577

Q33949356-6D2EA959-D169-4F47-8671-EF5A473B6954

P5875

Q33949356-55364E70-3458-47D8-9605-0230D2A24179

P698

Q33949356-DBAF5E07-2810-45F9-9D01-5626FBAB3D5F

P921

Q33949356-10DE7166-2092-408A-97DB-400DDEC58358

P356

JAMA.285.21.2743

P1433

Journal of the American Medical Association

P1476

Enzyme replacement therapy in Fabry disease: a randomized controlled trial.

@en

P2093

D F Moore

http://www.w3.org/2001/XMLSchema#string

H A Austin

http://www.w3.org/2001/XMLSchema#string

J B Kopp

http://www.w3.org/2001/XMLSchema#string

J E Balow

http://www.w3.org/2001/XMLSchema#string

R O Brady

http://www.w3.org/2001/XMLSchema#string

R Schiffmann

http://www.w3.org/2001/XMLSchema#string

S Sabnis

http://www.w3.org/2001/XMLSchema#string

T Weibel

http://www.w3.org/2001/XMLSchema#string

P304

2743-2749

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1001/JAMA.285.21.2743

http://www.w3.org/2001/XMLSchema#string

P407

P433

21

http://www.w3.org/2001/XMLSchema#string

P478

285

http://www.w3.org/2001/XMLSchema#string

P577

2001-06-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

11952155

http://www.w3.org/2001/XMLSchema#string

P698

11386930

http://www.w3.org/2001/XMLSchema#string

P921

Enzyme replacement therapy